The initiation of coverage by B. Riley Securities with a Buy rating and a specific price target of $1.20 is a strong positive endorsement for Perspective Therapeutics. This typically leads to increased investor confidence and can drive the stock price up in the short term, as it suggests a potential undervaluation at current levels.